Compare COE & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COE | BWAY |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.9M | 280.7M |
| IPO Year | 2016 | 2019 |
| Metric | COE | BWAY |
|---|---|---|
| Price | $41.36 | $17.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.50 |
| AVG Volume (30 Days) | 2.8K | ★ 73.6K |
| Earning Date | 12-05-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 213.09 |
| EPS | N/A | ★ 0.13 |
| Revenue | ★ $68,928,000.00 | $49,094,000.00 |
| Revenue This Year | N/A | $335.63 |
| Revenue Next Year | N/A | $22.10 |
| P/E Ratio | ★ N/A | $49.96 |
| Revenue Growth | ★ 93.05 | 27.08 |
| 52 Week Low | $12.98 | $7.84 |
| 52 Week High | $56.13 | $17.92 |
| Indicator | COE | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 36.73 | 64.84 |
| Support Level | $41.33 | $14.60 |
| Resistance Level | $42.95 | $15.56 |
| Average True Range (ATR) | 1.06 | 0.88 |
| MACD | -0.56 | 0.13 |
| Stochastic Oscillator | 25.75 | 99.40 |
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Group operates in seven principal geographical area: China, Hong Kong, Philippines, Singapore, Malaysia, Thailand and Saudi Arabia.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.